Short Interest in Avalon GloboCare Corp. (NASDAQ:ALBT) Increases By 1,180.8%

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,541,639 shares, an increase of 1,180.8% from the June 30th total of 120,361 shares. Based on an average daily volume of 4,865,720 shares, the short-interest ratio is currently 0.3 days. Currently, 14.0% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, June 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Avalon GloboCare presently has a consensus rating of “Sell”.

Avalon GloboCare Trading Down 1.1%

ALBT stock traded down $0.00 during midday trading on Friday, reaching $0.28. 9,336,703 shares of the company’s stock traded hands, compared to its average volume of 3,170,642. Avalon GloboCare has a 52-week low of $0.21 and a 52-week high of $4.74. The stock has a market cap of $4.05 million, a P/E ratio of -0.08 and a beta of -0.03. The stock’s 50-day moving average is $0.32 and its 200 day moving average is $0.57.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.